【摘要】 目的 :观察磺脲类药物格列吡嗪控释片 (瑞易宁 )治疗 2型糖尿病的有效性和安全性。方法 :选择无磺脲类药物继发失效的 2型糖尿病患者 97例 ,随机分入格列吡嗪控释片组 (观察组 )和格列苯脲组 (对照组 ) ,观察时间为 16wk(剂量调整期 8wk,维持期 8wk)。结果 :观察组降糖的有效率为 89 79% ,对照组为 89 5 8% ,两组间比较差异无显著意义 (X2 =0 0 0 0 2 ,P >0 0 5 )。治疗16wk后空腹血糖 (FBG)、餐后 2h血糖 ( 2hPBG)、糖化血红蛋白 (HbA1c)显著降低 (P <0 0 5 ) ,但两组比较差异无显著意义 (P >0 0 5 )。 2hPBG和C肽水平观察组低于对照组 (P <0 0 5 ) ,但FBG及C肽水平两组相似 (P >0 0 5 )。格列吡嗪控释片对肝、肾功能和血压无不良反应。观察组低血糖的发生率 [6 12 % ( 3 4 9) ]与对照组比较 [2 6 % ( 13 5 0 ) ],差异有显著意义 (X2 =7 4 14 ,P <0 0 1)。结论 :格列吡嗪控释片治疗 2型糖尿病疗效可靠、安全、顺应性好更多还原

【Abstract】 OBJECTIVE: To observe the efficacy and safety of glipizid-GITS in the treatment of type 2 diabetes. METHODS: 97 cases patients with type 2 diabetes without secondary failure to sulfonylureas were randomly assigned to glipizid-GITS group or glibenclamide group in ratio 1∶1 The whole observation lasted 16weeks.RESULTS:The results showed that both glipizid-GITS and glibenclamied led to a reduction of GHbA1C,the mean fasting and 2h postprandial blood glucose levels obviously decreased( P <0 05). Glipizid-GITS had less effect on increasing 2h postprandial serum insulin and C-peptide level than glibenclamide did ( P <0 05).Glipizid-GITS did not affect plasma lipid and the functions of liver and kidney.There was a lower incidence of hypoglycemia by glipizide than by glibenclamide (6 12%vs 26%, P <0 01).The efficacy rate of glipizide-GITS was 89 79%. CONCLUSION: Glipizide-GITS is effective and safe in the treatment of type 2 diabetes.更多还原